Henryk M.
- Country
- Poland
- Department
- NA
Research Overview
- Evaluation of Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Cystic Fibrosis Patients with 3849+10 Kb C->T Mutation
- Phase 2 Open-Label Study Evaluating Safety, Tolerability, and Efficacy of ARCT-032 (mRNA Encoding Human CFTR Gene) in Cystic Fibrosis Patients
- Evaluation of Nebulized BX004 in Adult Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Pulmonary Infection: A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 8 of 37 partner sites.
Specializations
Respiratory Medicine
Specializes in the investigation of therapeutic interventions for cystic fibrosis, with particular emphasis on evaluating novel inhaled treatments. The investigator focuses on understanding respiratory conditions and their management through innovative therapeutic approaches.
- Pulmonary Disease Management
- Respiratory Drug Development
- Inhaled Therapeutics
Expertise extends to analyzing drug safety profiles and tolerability in respiratory conditions.
Clinical Pharmacology
Conducts research in pharmacokinetics of respiratory medications, specifically examining drug absorption and distribution patterns in patients with respiratory disorders.
- Drug Safety Assessment
- Dose Optimization
- Treatment Tolerability
Investigates the relationship between drug dosing and therapeutic response in respiratory conditions.
Therapeutic Development
Focuses on evaluating preliminary efficacy of novel therapeutic agents for genetic respiratory disorders. Works on advancing treatment options for patients with inherited respiratory conditions.
- Treatment Innovation
- Clinical Response Assessment
- Patient Safety Monitoring
Examines the potential of new therapeutic compounds in respiratory medicine.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.